CANVAC 8 DHPPiL

Indications

• Pain management
• Post-surgical recovery
• Infections
• Chronic inflammatory diseases
• Neurological disorders

Dosage

Children: Paediatric dosing in dogs is also highly variable and should be determined by a veterinarian based on the specific medication and the puppy's age, weight, and overall health.

Adults: Dosage for adult dogs varies significantly based on the specific medication and condition being treated. It is essential to refer to a veterinary professional for accurate dosing.

Mechanism of action

The pharmacological actions in canines often depend on the specific medication being used. For instance, non-steroidal anti-inflammatory drugs (NSAIDs) used in dogs, such as carprofen, work by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thus reducing the formation of prostaglandins that mediate inflammation and pain. Antibiotics may exert their effects by inhibiting bacterial cell wall synthesis or protein synthesis, ultimately leading to bacterial cell death or growth inhibition.

Pharmacodynamics

The pharmacodynamics of drugs used in canines typically involve their interaction with biological systems to produce therapeutic effects. For analgesics, the primary effect is pain relief, while anti-inflammatories reduce swelling and inflammation. The efficacy of these medications can vary based on the individual dog's health status, age, and breed, necessitating careful monitoring and dose adjustments.

Pharmacokinetics

Pharmacokinetics in dogs can vary significantly based on the drug's formulation and the dog's metabolic rate. Generally, after administration, drugs are absorbed into the bloodstream, distributed to tissues, metabolized primarily in the liver, and excreted through the kidneys. Factors such as age, size, health conditions, and concurrent medications can influence these processes, impacting the drug's effectiveness and safety.

Pregnancy

Safety during pregnancy has not been established. Use should be avoided unless the potential benefits outweigh the risks.

Breast-feeding

Safety during breastfeeding has not been established. Caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct light. Keep out of reach of children.

Indications

• Clinical term 1
• Common term 1
• Clinical term 2
• Common term 2

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing guidelines.

Adults: Refer to the BNF for specific adult dosing guidelines.

Mechanism of action

Dose acts by modulating the activity of specific neurotransmitter receptors and ion channels, influencing various physiological pathways. Its precise mechanism may involve interactions with G-protein coupled receptors, leading to downstream signaling effects that impact cellular responses.

Pharmacodynamics

Dose exhibits a range of effects depending on the dosage and target tissues. It is known to alter neurotransmitter release, affect ion conductance, and influence metabolic pathways, thereby contributing to its therapeutic efficacy and potential side effects.

Pharmacokinetics

Dose is generally absorbed following administration, with peak plasma concentrations occurring within a specified timeframe. Its distribution is influenced by tissue binding and permeability across cell membranes. The drug is metabolized primarily in the liver, with metabolites being excreted via renal and biliary routes. The half-life can vary based on individual patient factors, including age, liver function, and other concurrent medications.

Indications

• Salmonella enteritidis infection
• Foodborne illness
• Gastroenteritis

Dosage

Children: Dosage for children should be determined based on weight and severity of symptoms. Refer to pediatric guidelines for specific dosing recommendations.

Adults: Treatment may vary based on the severity of the infection and the susceptibility of the strain to antibiotics. Refer to local guidelines for appropriate therapeutic regimens.

Mechanism of action

Salmonella enteritidis invades the intestinal epithelial cells, leading to inflammation and disruption of the intestinal barrier. It utilizes various virulence factors, including invasion proteins, to facilitate its entry into host cells and evade the host's immune response. The bacteria can also induce apoptosis in host cells, contributing to tissue damage and diarrhea.

Pharmacodynamics

Enteritidis infections provoke an immune response characterized by the activation of neutrophils and macrophages, leading to the release of pro-inflammatory cytokines. This immune response is responsible for the clinical manifestations of the infection, including fever and diarrhea. The inflammatory response can also lead to fluid secretion in the intestines, exacerbating diarrhea.

Pharmacokinetics

As a bacterial pathogen, Enteritidis does not follow traditional pharmacokinetics associated with drugs. Instead, its survival and replication depend on its ability to colonize the gastrointestinal tract and evade host immune mechanisms. Antibiotic treatment, if utilized, would depend on the sensitivity of the strain, with pharmacokinetic considerations being relevant to the chosen antimicrobial agents.

Pregnancy

Safety during pregnancy has not been established. Use only if potential benefit justifies potential risk to the fetus.

Breast-feeding

Caution is advised, as it is not known whether this drug is excreted in human milk.

Storage

Store in a cool, dry place, away from direct light. Maintain at room temperature unless otherwise specified.

Indications

• Fifth disease (erythema infectiosum)
• Aplastic crisis in patients with hemolytic anemia
• Parvovirus B19 infection in immunocompromised patients

Dosage

Children: There are no specific pharmacological treatments for parvovirus infections; management is supportive. In children, parvovirus B19 infection typically resolves on its own, and symptomatic treatment is

Adults: There are no specific pharmacological treatments for parvovirus infections; management is supportive. Adults with parvovirus B19 infection are generally advised to rest and manage symptoms such as fever and pain.

Mechanism of action

Parvovirus B19 infects erythroid progenitor cells in the bone marrow, leading to lysis of these cells and a subsequent decrease in red blood cell production. The virus attaches to its receptor, globoside (also known as P antigen), which is present on the surface of erythroid progenitor cells. This binding facilitates viral entry and replication, disrupting normal erythropoiesis.

Pharmacodynamics

Parvovirus B19's primary effect is on the hematopoietic system, particularly impacting the production of red blood cells. In immunocompetent individuals, infection typically results in mild symptoms and self-limiting disease. However, in individuals with compromised immune systems or underlying hematological conditions, the virus can lead to severe anemia and other complications due to its effect on erythroid progenitors.

Pharmacokinetics

Parvovirus does not follow traditional pharmacokinetic principles as it is a virus rather than a pharmaceutical agent. Its replication occurs intracellularly, and it is spread via respiratory droplets or blood. The incubation period ranges from 4 to 14 days, and viremia can persist for weeks. The immune response is crucial for clearing the virus, with specific antibodies developing within a few weeks of infection.

Adverse effects

• Fever
• Malaise
• Rash
• Joint pain
• Anemia
• Lethargy

Precautions

• Immunocompromised patients may experience more severe symptoms.
• Pregnant women should be cautious due to potential risks to the fetus.

Pregnancy

Parvovirus B19 infection during pregnancy can lead to serious complications, including fetal anemia and hydrops fetalis.

Breast-feeding

There is no evidence to suggest that parvovirus B19 is transmitted through breast milk.

Storage

Parvovirus is a virus and does not require storage in a conventional sense; however, specimens should be handled according to biosafety guidelines.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.